



UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO FACULTAD DE
MEDICINA DIVISIÓN DE ESTUDIOS DE POSGRADO

ASOCIACIÓN PARA EVITAR LA CEGUERA EN MÉXICO I.A.P. HOSPITAL "DR.
LUIS SÁNCHEZ BULNES"

**CAMBIOS EN EL FLUJO VASCULAR RETINIANO Y COROIDEO
POSTERIOR A LA INGESTA DE SILDENAFIL POR TOMOGRAFÍA
DE COHERENCIA ÓPTICA CON ANGIOGRAFÍA**

TESIS DE POSGRADO PARA OBTENER EL TITULO DE:
ESPECIALISTA EN OFTALMOLOGIA

PRESENTA:

DR. DAVID BERRONES MEDINA

ASESOR:

DR. RAÚL VELEZ MONTOYA

Adscrito departamento de Retina y Vítreo

CIUDAD DE MÉXICO, 2017



Universidad Nacional
Autónoma de México

Dirección General de Bibliotecas de la UNAM

Biblioteca Central



UNAM – Dirección General de Bibliotecas
Tesis Digitales
Restricciones de uso

DERECHOS RESERVADOS ©
PROHIBIDA SU REPRODUCCIÓN TOTAL O PARCIAL

Todo el material contenido en esta tesis esta protegido por la Ley Federal del Derecho de Autor (LFDA) de los Estados Unidos Mexicanos (México).

El uso de imágenes, fragmentos de videos, y demás material que sea objeto de protección de los derechos de autor, será exclusivamente para fines educativos e informativos y deberá citar la fuente donde la obtuvo mencionando el autor o autores. Cualquier uso distinto como el lucro, reproducción, edición o modificación, será perseguido y sancionado por el respectivo titular de los Derechos de Autor.

CAMBIOS EN EL FLUJO VASCULAR RETINIANO Y COROIDEO POSTERIOR A LA INGESTA DE SILDENAFIL POR TOMOGRAFÍA DE COHERENCIA ÓPTICA CON ANGIOGRAFÍA

Dr. David Berrones Medina, Residente de 3º año

Email: dr.berrones@gmail.com

Esta revisión fue hecha en la Asociación para Evitar la Ceguera en México, hospital “Dr. Luis Sánchez Bulnes”. Ubicado en calle Vicente García Torres No. 46, colonia Barrio San Lucas Coyoacán, CP 04030, ciudad de México; con número telefónico 1084-1400.

INDEX

	Page
Introduction.....	4
Objective.....	6
Methods.....	6
Results.....	8
Discussion.....	11
Conclusion.....	13
References.....	14

Introduction:

Optical Coherence Tomography Angiography (OCT-A) is a new non-invasive diagnostic tool that allows visualization of the retinal and choroidal circulation in real time. The study allows the estimation of the ocular vascular flow [1] and the theoretical quantification of the capillary density at different retinal anatomical zones. Although its role in patient care is still debatable, the study has shown promising results in demonstrating vascular changes occurring in common retinal pathologies like diabetic retinopathy, vascular occlusions, and choroidal neovascularization among others [2].

Sildenafil is a phosphodiesterase 5 and 6 (PDE-5, PDE-6) inhibitors that induce vasodilation. It is used in the treatment of pulmonary arterial hypertension and is currently the pharmacological first line treatment for erectile dysfunction. The drug achieves its biological effect by inducing the degradation of cyclic guanosine monophosphate (cGMP), enhancing the effect of nitric oxide and the inhibition of transmembrane influx of calcium and cell membrane hyperpolarization. The result is smooth muscle relaxation [3]. The recommended oral dose is 25-50mg to 100mg qd, three times per week. Doses above 100mg can increase the risk of systemic adverse effects like headaches, nasal congestion and flushing. The most common ocular adverse effects are changes in color and light perception, blurred vision, conjunctival hyperemia, ocular pain and photophobia. Less common ocular adverse effects are non-arteritic ischemic optic neuropathy [4], reversible increase in intraocular pressure [5], idiopathic serous macular detachment, central serous chorioretinopathy [6, 7], and ERG disturbances [8-10].

A precise explanation of the ocular adverse effects is still unknown. However, it has been hypothesized that changes in vascular flow of the retina and choroid could have an important role. Several studies have yielded mixed results. Those studies supporting this theory have shown that oral sildenafil can induce changes in choroidal thickness [11, 12], vascular flow [13-

16], and alteration in retinal electroretinogram [17]; and others that did not find changes in perimetry [18], flowmetry [19] and Doppler ecography [20]. Therefore, the purpose of the current study is to assess vascular changes in the retinal and choroidal circulation, by taking advantage all the capabilities of the OCT-A, after the oral ingestion of sildenafil in healthy volunteers.

Objective:

To describe changes in retina and choroidal flow by optical coherent tomography-angiography (OCT-A) after single dose of oral sildenafil.

Method:

Case and control, single center study. The study was conducted at *the Asociación para Evitar la Ceguera en México IAP*, Mexico City, Mexico and approved by the local Internal Review Board. The study was conducted according to the tenets of the Declaration of Helsinki and Good Clinical Practices guidelines. All sensitive data were managed according to the Mexican Federal Law for Protection of Personal Data in Possession of Individuals (NOM-024-SSA3-2010), which is the equivalent the Health Insurance Portability and Accountability Act (HIPAA) rules of 1996. All participants signed an informed consent form before enrollment.

We included patients between 18 and 40 years of age, with no relevant medical history. Patients with history of a hypersensitivity reaction to phosphodiesterase inhibitors or history of past adverse effect with oral sildenafil were excluded. General demographic data and biometric data (weight and height) were recorded at baseline. All participants were stratified randomized into two groups with a proportion of 2:1. Patients assigned to the study group received 50mg of oral sildenafil (Viagra®, Pfizer, New York, NY) and patients assigned to the control group received a sham pill the same size, color, and form.

Retinal and choroidal images were capture at baseline and 1 hours after the pill ingestion. Central macular thickness (CMT) and central choroidal thickness (CCT) were measured with optical coherent tomography (OCT) and Enhanced depth imaging-OCT (Spectralis HRA-OCT; Heidelberg Engineering, Heidelberg, Germany). Choroidal flow (CF), outer retina flow (ORF), retinal vascular density (RVD) and choroidal vascular density (CVD) were measured with OCT-A (AngioVue OCT-A system, Optovue Inc, Fremont, CA).

Statistical analysis was done using an Excel spreadsheet (Excel 2010; Microsoft Corp., Redmond, WA) with and XLSTAT application v18.06 (Addinsoft, New York, NY). Nominal variables were compared using a Mann-Whitney test with an alpha value of 0.05 for statistical significance.

Results:

We enrolled 20 eyes into the study group (Sildenafil 50mg) and 10 eyes into the control group (sham). In the study group, the mean age was 28.1 years, the mean weight was 73.6 kg, the mean height was 1.76 meters. In the control group, the mean age was 29.2 years, the mean weight was 70.4 kg. The mean height was 1.75 meters.

Results from the study and control group are summarized in table 1. In the study group, CCT increased significantly after 1 hour of sildenafil ingestion ($p<0.01$). The rest of the assessed variables in the study group did not have a significant change after sildenafil. In the control group, none of the assessed variables had a significant change after sham.

	Before	After
Sildenafil group		
CMT	280.4 ± 23.69µm	279.85 ± 22.80µm
CCT	354.45 ± 67.17µm	429.30 ± 82.87µm*
CF	1.95 ± 0.04 mm ²	1.87 ± 0.22 mm ²
ORF	1.21 ± 0.20 mm ²	1.31 ± 0.27 mm ²
RVD	52.6 ± 3.50%	53.6 ± 3.21%
CVD	66.6 ± 1.48%	67.28 ± 1.02%
Sham group		
CMT	266.60 ± 19.28µm	266.20 ± 19.02µm
CCT	397.10 ± 72.81µm	396.50 ± 68.48µm
CF	1.96 ± 0.05 mm ²	1.95 ± 0.05 mm ²
ORF	1.06 ± 0.23 mm ²	1.03 ± 0.23 mm ²
RVD	53.9 ± 2.16%	53.3 ± 3.45%
CVD	66.98 ± 1.06%	66.90 ± 1.50%

Table 1: CHANGE IN OCT BEFORE AND AFTER SILDENAFIL/SHAM. Comparison of variables before and after the ingestion of the pill for both groups. *CMT: central macular thickness, CCT: Central choroidal thickness, CF: Choroidal flow, ORF: Outer retinal flow, RVD: Retinal vascular density, CVD: Choroidal vascular density.* *Significance ($p < 0.01$).

Intergroup comparison between study and control group are summarized in table 2. The analysis showed that 1 hour after pills ingestion, the outer retinal flow increased significantly in the study group ($p < 0.01$). The rest of the assessed variables between groups did not have a

significant difference between them.

	Post Treatment Sildenafil group	Post Treatment Sham group
CMT	279.85 ± 22.80µm	266.20 ± 19.02µm
CCT	429.30 ± 82.87µm	396.50 ± 68.48µm
CF	1.87 ± 0.22 mm ²	1.95 ± 0.05 mm ²
ORF	1.31 ± 0.27 mm ²	1.03 ± 0.23 mm ² *
RVD	53.6 ± 3.21%	53.3 ± 3.45%
CVD	67.28 ± 1.02%	66.90 ± 1.50%

Table 2: RESULTS AFTER PILL ADMINISTRATION FOR BOTH GROUPS. Comparison of the variables for the study and control group 1 hour after the ingestion of sildenafil/sham. *CMT: central macular thickness, CCT: Central choroidal thickness, CF: Choroidal flow, ORF: Outer retinal flow, RVD: Retinal vascular density, CVD: Choroidal vascular density.*

*Significance ($p < 0.01$).

Discussion:

Optical Coherence Tomography Angiography is a novel diagnostic tool that can potentially impact ocular medical therapies in the future. It has been tried as an early diagnostic and assessment tool for age-related macular degeneration (AMD) [21-24], as a research tool in order to improve the current understanding of ischemic diseases that affect the different layers of the retinal microcirculation (diabetic retinopathy) [25, 26], cotton wool spots, acute macular neuroretinopathy, paracentral acute middle maculopathy, and macular telangiectasia type 2 among others [27-29].

The role of vascular flow changes in choroidal diseases is unknown. Evidence from peer-reviewed manuscripts have found a relationship between flow changes among different retinal layers and choroid with the pathogenesis of some of the most common chorioretinal diseases [30-33]. Changes in choroidal thickness (reduction) and in the density of superficial and deep retinal vessels have been associated with choroidal neovascularization [34]. A reduction in the total retinal and choroidal flow have been observed in patients with macular edema [35, 36], and finally, an increase in the total choroidal flow has been observed in patients with central serous retinopathy [37]. Since most of the ocular side effects of oral sildenafil are thought to be secondary to an idiosyncratic dilation of the retinal and choroidal vessels; the potential impact of this pharmacologic effect on the total vascular flow should be assessed. A major understanding of the mechanism associated with this phenomenon could aid us in preventing such adverse effects as well as improving our current understanding of the relationship of vascular flow and others chorioretinal diseases like central serous retinopathy.

The results of the current study are similar to previous reports reporting a significant increase in choroidal thickness measured by EDI-OCT. However, OCT-A results failed to demonstrate a significant change in choroidal blood flow. Outer retinal blood flow increased after sildenafil but

the capillary density of the retina remained unchanged. Nevertheless, our results may suggest that despite a local pharmacological effect secondary to sildenafil, the autoregulation mechanisms of the retinal and choroidal vasculature may prevent significant changes in vascular hemodynamics, at least in the short term, ensuring a constant blood flow and preventing blood stagnation and ischemic changes in healthy patients.

The current study has several limitations that we would like to address. First, the small sample can make us incur in an error type 2. The high variability in biometric values could affect the distribution volume of the drug among patients. Therefore, our patients could have responded differently to a fixed dose. There is a possibility that an ocular vascular effect could have been demonstrated if we had had adjusted the dose according to weight and height. Finally, all our patients were first-time users of sildenafil. Most of the ocular adverse effects of the drug occur in chronic users. There is a possibility that ocular changes due to sildenafil are due to the continue exposition to the drug, or to the association of a preexisting ocular condition with exposition to the drug.

In summary, our study found an increase in choroidal thickness and in the outer retinal flow that suggests vascular effect of sildenafil in the eye. No measurable data was found regarding the change in choroidal flow, despite the increase in choroidal thickness. The results may suggest that even with a local pharmacological effect of sildenafil, the vascular autoregulation mechanisms of the retina and choroid may prevent a significant change in vascular hemodynamics, at least in the short term, ensuring a constant blood flow and preventing blood stagnation and ischemia. Further studies with longer follow-up are needed in order to assess the role of chronic use of sildenafil on retinal vascular hemodynamics in healthy and diseased patients.

Conclusions: A single dose of oral sildenafil increases choroidal thickness, probably due to sildenafil-induced vasodilation.

Acknowledgments: None

Disclosure: Berrones, D: none, Velez-Montoya, R: none, Morales-Canton, V: none, Salcedo-Villanueva, G: none.

References:

1. J. Maram, S. Srinivas and S. R. Sadda, "*Evaluating ocular blood flow*," Indian J Ophthalmol, 65, 337-346, 2017.
2. K. Sambhav, S. Grover and K. V. Chalam, "*The Application of Optical Coherence Tomography Angiography in Retinal Diseases*," Surv Ophthalmol, 2017.
3. H. Sperling, M. C. Michel and H. Rubben, "*[Sildenafil (Viagra). Tolerance, contraindications, drug interactions]*," Urologe A, 38, 124-7, 1999.
4. H. Almuhtaseb, O. Kanavati and A. Lotery, "*Branch retinal vein occlusion secondary to sildenafil*," BMJ, 356, j753, 2017.
5. R. Gerometta, L. J. Alvarez and O. A. Candia, "*Effect of sildenafil citrate on intraocular pressure and blood pressure in human volunteers*," Exp Eye Res, 93, 103-7, 2011.
6. F. W. Fraunfelder and F. T. Fraunfelder, "*Central serous chorioretinopathy associated with sildenafil*," Retina, 28, 606-9, 2008.
7. E. Damar, Y. Toklu, A. Tuncel, et al., "*Does therapeutic dose of sildenafil citrate treatment lead to central serous chorioretinopathy in patients with erectile dysfunction?*," Am J Mens Health, 7, 439-43, 2013.
8. M. M. Moschos and E. Nitoda, "*Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction*," Drug Des Devel Ther, 8, 3407-3413, 2016.
9. A. Stockman, L. T. Sharpe, A. Tufail, P. D. Kell, C. Ripamonti and G. Jeffery, "*The effect of sildenafil citrate (Viagra) on visual sensitivity*," J Vis, 7, 4, 2007.

10. J. Martins, B. Kolomiets, R. Caplette, et al., "*Sildenafil Acutely Decreases Visual Responses in ON and OFF Retinal Ganglion Cells*," Invest Ophthalmol Vis Sci, 56, 2639-48, 2015.
11. D. Y. Kim, R. H. Silverman, R. V. Chan, et al., "*Measurement of choroidal perfusion and thickness following systemic sildenafil (Viagra((R)))*," Acta Ophthalmol, 91, 183-8, 2013.
12. S. K. Vance, Y. Imamura and K. B. Freund, "*The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography*," Retina, 31, 332-5, 2011.
13. E. Kurtulan, A. Gulcu, M. Secil, I. Celebi, G. Aslan and A. A. Esen, "*Effects of sildenafil on ocular perfusion demonstrated by color Doppler ultrasonography*," Int J Impot Res, 16, 244-8, 2004.
14. M. Koksal, H. Ozdemir, S. Kargi, et al., "*The effects of sildenafil on ocular blood flow*," Acta Ophthalmol Scand, 83, 355-9, 2005.
15. Z. Yuan, T. W. Hein, R. H. Rosa, Jr. and L. Kuo, "*Sildenafil (Viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition*," Invest Ophthalmol Vis Sci, 49, 720-5, 2008.
16. A. Harris, L. Kagemann, R. Ehrlich, Y. Ehrlich, C. R. Lopez and V. A. Purvin, "*The effect of sildenafil on ocular blood flow*," Br J Ophthalmol, 92, 469-73, 2008.
17. J. K. Luu, A. V. Chappelow, T. J. McCulley and M. F. Marmor, "*Acute effects of sildenafil on the electroretinogram and multifocal electroretinogram*," Am J Ophthalmol, 132, 388-94, 2001.

18. S. O. Dundar, A. Topalo Gcaron Lu, M. Dundar and I. Kocak, "*Effects of sildenafil on blue-on-yellow and white-on-white Humphrey perimetry in 3 months regular use,*" Eye (Lond), 20, 810-3, 2006.
19. T. I. Metelitsina, J. E. Grunwald, J. C. DuPont and G. S. Ying, "*Effect of Viagra on the foveolar choroidal circulation of AMD patients,*" Exp Eye Res, 81, 159-64, 2005.
20. A. P. Costa, A. M. Lima, L. H. da Silva, R. de Oliveira Alves Carvalho, A. V. do Amaral and N. C. Borges, "*Ocular perfusion pressure and color Doppler imaging of the external ophthalmic artery of rabbits treated with sildenafil citrate,*" BMC Vet Res, 12, 149, 2016.
21. Y. Jia, S. T. Bailey, D. J. Wilson, et al., "*Quantitative optical coherence tomography angiography of choroidal neovascularization in age-related macular degeneration,*" Ophthalmology, 121, 1435-44, 2014.
22. E. Moul, W. Choi, N. K. Waheed, et al., "*Ultrahigh-speed swept-source OCT angiography in exudative AMD,*" Ophthalmic Surg Lasers Imaging Retina, 45, 496-505, 2014.
23. M. M. Castillo, G. Mowatt, A. Elders, et al., "*Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review,*" Ophthalmology, 122, 399-406, 2015.
24. D. Y. Kim, J. Fingler, R. J. Zawadzki, et al., "*Optical imaging of the chorioretinal vasculature in the living human eye,*" Proc Natl Acad Sci U S A, 110, 14354-9, 2013.
25. N. Takase, M. Nozaki, A. Kato, H. Ozeki, M. Yoshida and Y. Ogura, "*Enlargement of Foveal Avascular Zone in Diabetic Eyes Evaluated by En Face Optical Coherence Tomography Angiography,*" Retina, 35, 2377-83, 2015.

26. G. Coscas, M. Lupidi and F. Coscas, "*Optical Coherence Tomography Angiography in Diabetic Maculopathy*," Dev Ophthalmol, 60, 38-49, 2017.
27. A. Nagiel, S. R. Sadda and D. Sarraf, "*A Promising Future for Optical Coherence Tomography Angiography*," JAMA Ophthalmol, 133, 629-30, 2015.
28. E. Rahimy, D. Sarraf, M. L. Dollin, J. D. Pitcher and A. C. Ho, "*Paracentral acute middle maculopathy in nonischemic central retinal vein occlusion*," Am J Ophthalmol, 158, 372-380 e1, 2014.
29. R. F. Spaide, J. M. Klancnik, Jr. and M. J. Cooney, "*Retinal vascular layers in macular telangiectasia type 2 imaged by optical coherence tomographic angiography*," JAMA Ophthalmol, 133, 66-73, 2015.
30. N. V. Palejwala, Y. Jia, S. S. Gao, et al., "*Detection of Nonexudative Choroidal Neovascularization in Age-Related Macular Degeneration with Optical Coherence Tomography Angiography*," Retina, 35, 2204-11, 2015.
31. L. Roisman, Q. Zhang, R. K. Wang, et al., "*Optical Coherence Tomography Angiography of Asymptomatic Neovascularization in Intermediate Age-Related Macular Degeneration*," Ophthalmology, 123, 1309-19, 2016.
32. G. Querques, M. Srour, N. Massamba, et al., "*Functional characterization and multimodal imaging of treatment-naive "quiescent" choroidal neovascularization*," Invest Ophthalmol Vis Sci, 54, 6886-92, 2013.
33. J. D. Gass, "*Serous retinal pigment epithelial detachment with a notch. A sign of occult choroidal neovascularization*," Retina, 4, 205-20, 1984.

34. L. Toto, E. Borrelli, L. Di Antonio, P. Carpineto and R. Mastropasqua, "*Retinal Vascular Plexuses' Changes in Dry Age-Related Macular Degeneration, Evaluated by Means of Optical Coherence Tomography Angiography*," *Retina*, 36, 1566-72, 2016.
35. M. Okamoto, M. Yamashita, T. Sakamoto and N. Ogata, "*Choroidal Blood Flow and Thickness as Predictors for Response to Anti-Vascular Endothelial Growth Factor Therapy in Macular Edema Secondary to Branch Retinal Vein Occlusion*," *Retina*, 2017.
36. B. Lee, E. A. Novais, N. K. Waheed, et al., "*En Face Doppler Optical Coherence Tomography Measurement of Total Retinal Blood Flow in Diabetic Retinopathy and Diabetic Macular Edema*," *JAMA Ophthalmol*, 135, 244-251, 2017.
37. M. Nicolo, R. Rosa, D. Musetti, M. Musolino, M. Saccheggiani and C. E. Traverso, "*Choroidal Vascular Flow Area in Central Serous Chorioretinopathy Using Swept-Source Optical Coherence Tomography Angiography*," *Invest Ophthalmol Vis Sci*, 58, 2002-2010, 2017.